Dexcom Issues Safety Alert Over Stolen G7 Sensors Diverted to Unauthorized Resellers

Dexcom has alerted the public to a breach involving its G7 continuous glucose monitoring system. Two batches of the devices, which had been designated as scrap due to quality control failures, were diverted from a destruction vendor and subsequently distributed through unauthorized commercial channels across the United States.

The sensors in question were originally flagged as defective and handed over to a third-party recycling and destruction firm as part of standard quality assurance procedures. During subsequent audits of quality metrics and inventory, Dexcom determined that certain units from these batches had not been properly destroyed. Instead, the company found that unauthorized parties had obtained and resold the devices.

Dexcom identified the compromised batches as lot 1725204004 and lot 1725069002. "At this time, Dexcom has identified two lots of Dexcom G7 sensors (1725204004 and 1725069002) that were stolen, sold and used by some customers," the company stated.

Potential safety concerns for users

The stolen units present distinct health hazards depending on which batch they came from. Devices from lot 1725204004 lack proper sterilization procedures, elevating the likelihood of bacterial skin infections in users. Units from lot 1725069002 exhibit a higher rate of internal testing defects that could prevent the sensor from delivering glucose readings to patients.

To date, Dexcom reports no documented cases of serious medical complications stemming from use of these compromised devices.

Unauthorized distributor identified in resale chain

Investigation traced the stolen sensors to Pharmsource LLC, an Atlanta-area pharmaceutical distributor not authorized by Dexcom to sell its products. The firm supplies various independent pharmacies and medical equipment vendors throughout the country.

"Nothing matters more to Dexcom than the safety of our users and maintaining the trust of the diabetes community," stated Jake Leach, Dexcom's president and chief executive. "We are treating this matter with the utmost seriousness and are working closely with regulators and other authorities to ensure user safety, determine exactly how this product was stolen and hold the perpetrators fully accountable for their crimes."

Pharmsource has rejected allegations of involvement in the theft itself. According to statements provided to MobiHealthNews, a company representative stated that Pharmsource procured the sensors from licensed suppliers and "had no way of knowing the product had been slated for destruction." The distributor indicated it "immediately conducted a thorough audit" upon discovering the situation and is assisting with the investigation.

Customer notification and replacement steps

The problem predominantly impacts patients within the United States. Dexcom has begun reaching out to affected customers via email, phone, and other communication methods.

Individuals possessing sensors from the affected batches should discontinue use immediately and request replacement units from Dexcom. The company has created a digital verification system enabling customers to determine if their particular devices are part of the recall.

Pharmacy chains and medical equipment suppliers that obtained inventory from Pharmsource are being advised to conduct thorough stock reviews. Dexcom emphasized that sensors obtained through its authorized distribution network remain unaffected by this incident.